Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 1.44 -0.05 (3.36%)
Day High: 1.49
Day Low:  1.43
Volume:    318,848
4:00 PM ET
Apr 28, 2017

Delayed ~20 min., by eSignal.